AbbVie

News

Morphic loses second partner as J&J exits integrin alliance

Morphic Therapeutic has lost Johnson & Johnson's Janssen Pharma as a partner, following the termination of an alliance to develop drugs targeting integrins first agreed in 2019.

News

AbbVie, Lilly pull out of UK voluntary drug pricing agreemen...

Two top pharma companies have exited the UK's voluntary medicines pricing agreement in protest at what the industry has said is a "punitive" system of revenue clawbacks, casting doubt on th

News

3d illustration of molecule model. Science background with molecules and atoms

AbbVie, Anima Biotech announce collaboration worth $580M plu...

AbbVie and Anima Biotech have

News

AbbVie claims key approval for Vraylar in depression

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes

News

ASH: CD20 bispecific antibodies take centre stage in lymphom...

As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n

News

GSK, J&J, and AZ head this year's access to medicines rankin...

The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies for their efforts to improve delivery of medicines to lower income countries – sees GSK re

Morphic loses second partner as J&J exits integrin alliance

AbbVie, Lilly pull out of UK voluntary drug pricing agreemen...

AbbVie, Anima Biotech announce collaboration worth $580M plu...

AbbVie claims key approval for Vraylar in depression

ASH: CD20 bispecific antibodies take centre stage in lymphom...

GSK, J&J, and AZ head this year's access to medicines rankin...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

AbbVie

Editor's Picks